Bristol Myers Squibb Company $BMY Stock: Phoenix Financial Ltd. Lowers Stake

Phoenix Financial Ltd. reduced its stake in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 59.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,170 shares of the biopharmaceutical company’s stock after selling 68,084 shares during the quarter. Phoenix Financial Ltd.’s holdings in Bristol Myers Squibb were worth $2,884,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in BMY. Pinion Investment Advisors LLC raised its holdings in Bristol Myers Squibb by 3.8% during the 3rd quarter. Pinion Investment Advisors LLC now owns 4,316 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 158 shares during the last quarter. Altura Wealth Advisors Inc. lifted its position in shares of Bristol Myers Squibb by 1.2% in the 3rd quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock worth $856,000 after purchasing an additional 161 shares during the period. Capital City Trust Co. FL lifted its position in shares of Bristol Myers Squibb by 0.7% in the 3rd quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock worth $1,455,000 after purchasing an additional 167 shares during the period. Eagle Bay Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 2.6% in the 3rd quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock valued at $408,000 after purchasing an additional 168 shares during the last quarter. Finally, Blue Bell Private Wealth Management LLC boosted its stake in shares of Bristol Myers Squibb by 21.1% in the 3rd quarter. Blue Bell Private Wealth Management LLC now owns 969 shares of the biopharmaceutical company’s stock valued at $60,000 after purchasing an additional 169 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Trading Down 0.1%

Shares of BMY stock opened at $63.39 on Monday. Bristol Myers Squibb Company has a fifty-two week low of $45.26 and a fifty-two week high of $68.64. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. The stock has a 50 day simple moving average of $61.90 and a two-hundred day simple moving average of $60.31. The company has a market cap of $129.57 billion, a P/E ratio of 14.06, a PEG ratio of 0.33 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.25. The firm had revenue of $13.07 billion for the quarter, compared to analysts’ expectations of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.63 EPS. Research analysts forecast that Bristol Myers Squibb Company will post 6.46 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Investors of record on Friday, October 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date was Friday, October 2nd. Bristol Myers Squibb’s payout ratio is presently 55.88%.

Key Stories Impacting Bristol Myers Squibb

Here are a few of the latest stories about BMY:

  • Positive Sentiment: Bristol Myers is working to expand Camzyos’ reach, while Eliquis remains an important contributor to its cardiovascular franchise. Sustained growth in these products could help support revenue. Can BMY Sustain Growth in Its Cardiovascular Franchise?
  • Neutral Sentiment: The company plans to unify research and development under one structure, aiming to bring scientific and clinical teams together to speed development and use new technologies. The departure of research chief Robert Plenge adds transition risk, so the impact will depend on execution. BMS sets unified research and development structure for 2027
  • Negative Sentiment: Zacks Research cut several earnings forecasts, including FY2026 EPS to $6.44 from $6.86 and FY2028 EPS to $4.77 from $5.21; it also reduced its Q4 2026 and Q2 2027 estimates. These revisions point to a softer earnings outlook, although the firm maintained a Hold rating. Bristol Myers Squibb analyst estimates

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Bristol Myers Squibb in a research report on Monday, October 19th. Zacks Research lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 22nd. Jefferies Financial Group restated a “buy” rating and issued a $76.00 target price on shares of Bristol Myers Squibb in a report on Monday, October 12th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Finally, TD Cowen started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They set a “buy” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $65.46.

View Our Latest Stock Analysis on Bristol Myers Squibb

Insiders Place Their Bets

In other Bristol Myers Squibb news, Director Julia A. Haller sold 3,800 shares of the firm’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares in the company, valued at approximately $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.05% of the stock is owned by insiders.

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Featured Articles

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.